OrganoPlate UF enables physiologically relevant tissue models by using unidirectional, gravity-driven flow, removing the need for external pumps. This approach simplifies operation while maintaining biological accuracy. With support for up to 512 chips in a single setup, researchers can conduct large-scale studies efficiently.
Features of OrganoPlate UF
• Unidirectional flow: Better replicates blood circulation, making it suitable for cardiovascular, oncology, and immunology research.
• Pump-free, gravity-driven design: Reduces complexity while maintaining conditions similar to the human body.
• Compatible with standard lab equipment: Works with existing liquid handling and imaging systems for efficient, high-throughput analysis.
• Supports long-term studies: Designed for extended culture of complex tissues, including those for chronic disease research.
Expanding Research Possibilities
“For over a decade, the MIMETAS OrganoPlate has been used worldwide to study human disease,” said Bas Trietsch, MIMETAS co-founder. “With UniFlow, we now offer unidirectional flow that closely mimics natural circulation while keeping our system easy to use.”
OrganoPlate UF is already integrated into MIMETAS’ liver, lung, brain, vasculature, and tumor models, supporting research in metabolic, cardiovascular, immunological, and cancer studies. The platform is now available as part of MIMETAS’ research services.
About MIMETAS
MIMETAS (Leiden, Netherlands) develops human-relevant disease models for drug discovery and development. The OrganoPlate® platform powers research for leading pharmaceutical companies worldwide. Founded in 2013, MIMETAS operates in Europe, Asia, and the USA. The company is based at Leiden Bio Science Park, a leading hub for life sciences innovation in the Netherlands.
A joint effort between Leiden University's Professor Ubbink's lab and ZoBio's Assay Development and Screening team has advanced fragment-based drug discovery targeting membrane...
Researchers at Leiden University Medical Center (LUMC), in collaboration with Erasmus MC and the Oncode Institute, have developed a novel vaccine targeting non-small cell lung...
Leiden University Medical Center (LUMC) has achieved a national milestone by treating the first Dutch patient with an autoimmune disease using CAR-T cell therapy. This approach,...